Analysts Set Geron Co. (NASDAQ:GERN) Price Target at $5.50

Shares of Geron Co. (NASDAQ:GERNGet Rating) have received an average rating of “Hold” from the six analysts that are covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $5.50.

GERN has been the topic of a number of recent analyst reports. Zacks Investment Research cut Geron from a “hold” rating to a “sell” rating in a report on Tuesday, March 15th. B. Riley restated a “buy” rating on shares of Geron in a research note on Friday, March 11th. StockNews.com initiated coverage on Geron in a research note on Thursday, March 31st. They set a “sell” rating on the stock. Finally, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Geron in a research note on Friday, March 11th.

GERN traded down $0.07 during trading hours on Monday, reaching $1.41. The company’s stock had a trading volume of 1,640,238 shares, compared to its average volume of 2,437,518. Geron has a fifty-two week low of $0.99 and a fifty-two week high of $2.23. The stock has a market cap of $456.46 million, a PE ratio of -3.92 and a beta of 1.09. The business’s 50-day moving average is $1.30 and its 200-day moving average is $1.31. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.11 and a quick ratio of 4.11.

Geron (NASDAQ:GERNGet Rating) last released its quarterly earnings data on Thursday, March 10th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Geron had a negative net margin of 8,335.39% and a negative return on equity of 70.87%. The business had revenue of $1.04 million during the quarter, compared to analyst estimates of $0.10 million. During the same quarter in the prior year, the company posted ($0.07) earnings per share. Analysts expect that Geron will post -0.44 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jump Financial LLC acquired a new stake in shares of Geron in the third quarter valued at $36,000. Wedbush Securities Inc. raised its stake in shares of Geron by 90.8% in the fourth quarter. Wedbush Securities Inc. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 11,900 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in shares of Geron in the third quarter valued at $30,000. BlackRock Inc. raised its stake in shares of Geron by 0.8% in the third quarter. BlackRock Inc. now owns 25,511,801 shares of the biopharmaceutical company’s stock valued at $34,951,000 after acquiring an additional 191,723 shares in the last quarter. Finally, Advisor Group Holdings Inc. raised its stake in shares of Geron by 6.7% in the third quarter. Advisor Group Holdings Inc. now owns 175,079 shares of the biopharmaceutical company’s stock valued at $240,000 after acquiring an additional 10,980 shares in the last quarter. Institutional investors and hedge funds own 41.10% of the company’s stock.

Geron Company Profile (Get Rating)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

Featured Articles

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.